ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 689

Prednisone, Disease Activity and Hypertension Independently Predict Cataracts in Systemic Lupus Erythematosus (SLE)

Khaled Alderaan1, Vuk Sekicki2, Laurence S. Magder3 and Michelle Petri4, 1King Fahad Specilaist Hospital, Dammam, Saudi Arabia, 2Medicine, Saint Agnes Hospital, Baltimore, MD, 3Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, 4Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Treatment and Management Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Cataract is the most common ocular damage in SLE.  It is the second most frequent item in the SLICC/ACR Damage Index.  Apart from cumulative corticosteroid doses, there are virtually no reports on other risk factors for cataract in SLE population.  We report on a large prospective study of cataract risk factors in SLE.

Methods: The analysis was based on the follow-up experience prior to age 60 of 2109 SLE patients who had not had a cataract prior to cohort entry.  Patients saw their ophthalmologist every 6 months.  Cataract was defined by the SLICC/ACR Damage Index.  The rate of incident cataract was calculated in subsets defined by patient characteristics and history.  Multivariable logistic regressions were fit to identify predictors of cataract while controlling for potential confounding variables.

Results: The patients were 93% female, 54% Caucasian, and 39% African-American.  The analysis was based on 11,887 persons-years of follow up, with median follow up time of 4.1 years per patient.  During this follow-up we observed 157 new cases of cataract, for an incidence of 13.2 per 1000 persons-years.  We estimated that the risk of being diagnosed with a cataract by age 60 was 28%.  Table 1 shows the results of a multivariate regression model.  Adjusting for other predictors, a cumulative prednisone dose equivalent to 10 mg/day for 10 years was a strong predictor of cataract (RR=3.1, P=0.0005).  Disease activity measured by SLEDAI (P =0.0005) and higher systolic blood pressure (P =0.0006) were associated with cataract.  Duration of SLE, diabetes mellitus, smoking, cholesterol, renal involvement, immunological profile and medication history, other than prednisone, were not associated with cataract. 

Conclusion: Cataract development in SLE patients is multifactorial with cumulative prednisone doses, systolic blood pressure and disease activity all playing an independent role.

Table 1: Independent Predictors of Cataract Based on a Multivariable Model

 

Predictor

Comparisons

Rate Ratio

(95% confidence interval)

P-value

 

Age

Per 10 year increase

2.0 (1.7, 2.4)

<0.0001

 

Mean Systolic BP during

prior cohort visits > 140 mmHg

Yes vs. no

2.2 (1.4, 3.3)

0.0006

 

Mean total cholesterol

Per 50 mg/dl increase

1.1 (1.0, 1.2)

0.22

 

Diabetes mellitus

Yes/no

1.3 (0.9, 2.0)

0.22

 

Mean SELENA-SLEDAI

 

Per 2 point increase

1.3 (1.1, 1.5)

0.0005

Cumulative Corticosteroid

    Exposure1

< 36492 mg vs. none

3650-10,9493 vs. none

10,950-36,4994 vs. none

36,5005 + vs. none

1.1 (0.5, 2.5)

1.1 (0.5, 2.3)

2.3 (1.3, 4.3)

3.1 (1.6, 5.7)

0.77

0.87

0.0065

0.0005

1 Includes prednisone history prior to cohort entry

2 Exposure equivalent to <10 mg/day for 1 year

3 Exposure equivalent to 10 mg/day for 1-3 years

4 Exposure equivalent to 10 mg/day for 3-10 years

5 Exposure equivalent to 10 mg/day for 10+ years


Disclosure:

K. Alderaan,
None;

V. Sekicki,
None;

L. S. Magder,
None;

M. Petri,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prednisone-disease-activity-and-hypertension-independently-predict-cataracts-in-systemic-lupus-erythematosus-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology